Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
23 3월 2022 - 8:46PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
under
the Securities Exchange Act of 1934
For
the month of March 2022
Commission
File Number: 001-40106
4D
pharma plc
(Translation
of Registrant’s name into English)
5th
Floor, 9 Bond Court
Leeds
LS1
2JZ
United
Kingdom
Tel:
+44 (0) 113 895 013
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
On
March 23, 2022, 4D pharma plc (the “Company,” “4D,” “4D pharma,” “we,” “us”
or “our”) issued a press release entitled “4D pharma Announces Positive Interim Results from the Phase I/II Study of
the Combination of MRx0518 and KEYTRUDA® (pembrolizumab) for the Treatment of Renal Cell Carcinoma.”
A
copy of the press release is attached as Exhibit 99.1 to this current report on Form 6-K and is incorporated by reference herein.
INDEX
TO EXHIBITS
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
4D
pharma plc |
|
|
Date:
March 23, 2022 |
/s/
Duncan Peyton |
|
Duncan
Peyton |
|
Chief
Executive Officer |
4D Pharma (NASDAQ:LBPS)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
4D Pharma (NASDAQ:LBPS)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
4D Pharma PLC (나스닥)의 실시간 뉴스: 최근 기사 0
More 4d Pharma Plc News Articles